Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

A Clinical and Laboratory Evaluation of Methionine Cycle-Transsulfuration and Androgen Pathway Markers in Children with Autistic Disorders

Geier D.A.a · Geier M.R.b

Author affiliations

aPresident, MedCon, Inc., 14 Redgate Ct., Silver Spring, MD 20905, USA, Tel. +1 301 384 6988, E-Mail DavidAllenGeier@comcast.net, and bPresident, The Genetic Centers of America, 14 Redgate Ct., Silver Spring, MD 20905, USA, Tel. +1 301 989 0548, Fax +1 301 989 1543, E-Mail mgeier@comcast.net

Related Articles for ""

Horm Res 2006;66:182–188

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: September 20, 2006
Issue release date: September 2006

Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 3

ISSN: 1663-2818 (Print)
eISSN: 1663-2826 (Online)

For additional information: https://www.karger.com/HRP

Abstract

Background/Aims: The prevalence of autism spectrum disorders (ASDs) is 1 in 300 children in the US. ASDs are characterized by impairments in social relatedness and communication, repetitive behaviors, abnormal movement patterns, and sensory dysfunction. Pre-pubertal age children with ASDs were assessed for metabolites in the methionine cycle-transsulfuration and androgen pathways, and for present physical development/behaviors indicative of hyperandrogenicity. Methods: The Institutional Review Board of the Institute for Chronic Illnesses (Office for Human Research Protections, US Department of Health and Human Services IRB number: IRB00005375) approved the present study. Sixteen consecutive pre-pubertal age children (≤11 years old; mean ± SD: 5.9 ± 2.1 years old) with previously diagnosed ASDs that presented to the Genetic Centers of America for outpatient care were evaluated. Results: Significantly (p < 0.01) increased levels of serum/plasma dehydroepiandrosterone and serum total testosterone relative to the age- and sex-specific normal laboratory reference ranges were observed. Conversely, serum follicle-stimulating hormone levels were significantly (p < 0.01) decreased. Plasma-reduced glutathione (p < 0.01), plasma cysteine (p < 0.01), plasma methionine (p < 0.01), serum cystathionine (p < 0.05), and serum homocysteine (p < 0.01) were all significantly decreased. Conclusion: The results suggest a possible cyclical interaction between the methionine cycle-transsulfuration and androgen pathways in some children with ASDs.

© 2006 S. Karger AG, Basel


References

  1. Bertrand J, Mars A, Boyle C, Bove F, Yeargin-Allsopp M, Decoufle P: Prevalence of autism in a United States population: the Brick Township, New Jersey, investigation. Pediatrics 2001;108:1155–1161.
  2. Eigsti IM, Shapiro T: A systems neuroscience approach to autism: biological, cognitive, and clinical perspectives. Ment Retard Dev Disabil Res Rev 2003;9:205–215.
  3. White JF: Intestinal pathology in autism. Exp Biol Med (Maywood) 2003;228:639–649.
  4. Sweeten TL, Bowyer SL, Posey DJ, Halberstadt GM, McDougle CJ: Increased prevalence of familial autoimmunity in probands with pervasive developmental disorders. Pediatrics 2003;112:E420–E424.
    External Resources
  5. Bolte S, Poustka F: The relation between general cognitive level and adaptive behavior domains in individuals with autism with and without comorbid mental retardation. Child Psychiatry Hum Dev 2002;33:165–172.
  6. Geier MR, Geier DA: The potential importance of steroids in the treatment of autistic spectrum disorders and other disorders involving mercury toxicity. Med Hypotheses 2005;64:946–954.
  7. Werner E, Dawson G: Validation of the phenomenon of autistic regression using home videotapes. Arch Gen Psychiatry 2005;62:889–895.
  8. James SJ, Culter P, Melnyk S, Jernigan S, Janak L, Gaylor DW, Neubrander JA: Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 2004;80:1611–1617.
  9. Ryan RA, Carrol J: Studies on a 3-beta-hydroxysteroid sulphotransferase from rat liver. Biochim Biophys Acta 1976;429:391–401.
  10. Strous RD, Golubchik P, Maayan R, Mozes T, Tuati-Werner D, Weizman A, Spivak B: Lowered DHEA-S plasma levels in adult individuals with autistic disorder. Eur Neuropsychopharmacol 2005;15:305–309.
  11. Tordjman S, Ferrari P, Sulmont V, Duyme M, Roubertoux P: Androgenic activity in autism. Am J Psychiatry 1997;154:1626–1627.
  12. Baron-Cohen S, Knickmeyer RC, Belmonte MK: Sex differences in the brain: implications for explaining autism. Science 2005;310:819–823.
  13. Siddiqi SU, Van Dyke DC, Donohoue P, McBrien DM: Premature sexual development in individuals with neurodevelopmental disabilities. Dev Med Child Neurol 1999;41:392–395.
  14. Giltay EJ, Hoogeveen EK, Elbers JM, Gooren LJ, Asscheman H, Stehouwer CD: Effects of sex steroids on plasma total homocysteine levels: a study in transsexual males and females. J Clin Endocrinol Metab 1998;83:550–553.
  15. Giltay EJ, Verhoef P, Gooren LJ, Geleijnse JM, Schouten EG, Stehouwer CD: Oral and transdermal estrogens both lower plasma total homocysteine in male-to-female transsexuals. Atherosclerosis 2003;168:139–146.
  16. Vrbikova J, Tallova J, Bicikova M, Dvorakova K, Hill M, Starka L: Plasma thiols and androgen levels in polycystic ovary syndrome. Clin Chem Lab Med 2003;41:216–221.
  17. Boris M, Goldblatt A, Galanko J, James SJ: Association of 5,10-Methylenetetrathydrofolate reductase (MTHFR) gene polymorphisms with autistic spectrum disorders. J Am Phys Surg 2004;9:106–108.
  18. Pasca SP, Nemes B, Vlase L, Gagvi CE, Dronca E, Miu AC, Dronca M: High levels of homocysteine and low serum paraoxonase 1 arylesterase activity in children with autism. Life Sci 2006;78:2244–2248.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: September 20, 2006
Issue release date: September 2006

Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 3

ISSN: 1663-2818 (Print)
eISSN: 1663-2826 (Online)

For additional information: https://www.karger.com/HRP


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.